Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use. According to the press release, the training program underscores Regentis's commitment to ensuring surgeons are proficient with the device before widespread use.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. Regentis believes that by establishing a strong educational foundation in Europe, it can replicate success in other regions.
The announcement comes as Regentis advances its European commercial launch plans following CE Mark approval. The company expects that the training activities will help build confidence among orthopedic surgeons, potentially accelerating the adoption of GelrinC across Europe. The Centers of Excellence will serve as hubs for ongoing education and clinical support, ensuring that surgeons have access to the latest techniques and outcomes data.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis's Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The company's forward-looking statements involve risks and uncertainties as detailed in its SEC filings, and it undertakes no duty to update this information unless required by law. For more details, see the full terms of use and disclaimers on the InvestorBrandNetwork website.
